Table 2. Univariate and multivariate analyses of baseline factors associated with SVR12 in patients with HCV infection (all GTs)§.
| Factors | Category | Univariate Analysis |
Multivariate Analysis |
||
|---|---|---|---|---|---|
| Odds Ratio (95% CI) | p-Value | Odds Ratio (95% CI) | p-Value | ||
| Age, years | ≤60 | 1 (Referent) | 1 (Referent) | ||
| >60 | 0.72 (0.60–0.87) | 0.001 | 0.74 (0.59–0.92) | 0.01 | |
| Sex | Female | 1 (Referent) | 1 (Referent) | ||
| Male | 0.88 (0.73–1.05) | 0.15 | 0.91 (0.74–1.11) | 0.33 | |
| Ethnicity | Non-Asian | 1 (Referent) | 1 (Referent) | ||
| Asian | 1.94 (1.51–2.49) | < 0.001 | 1.81 (1.30–2.53) | < 0.001 | |
| Prior treatment | No | 1 (Referent) | 1 (Referent) | ||
| Yes | 0.57 (0.47–0.69) | < 0.001 | 0.64 (0.52–0.78) | < 0.001 | |
| Liver fibrosis | Non-cirrhosis | 1 (Referent) | 1 (Referent) | ||
| Compensated cirrhosis | 0.45 (0.37–0.55) | < 0.001 | 0.55 (0.44–0.68) | < 0.001 | |
| Decompensated cirrhosis | 0.18 (0.13–0.24) | < 0.001 | 0.20 (0.14–0.29) | < 0.001 | |
| HCC | Non-HCC | 1 (Referent) | 1 (Referent) | ||
| Ablated HCC | 0.56 (0.42–0.75) | < 0.001 | 0.86 (0.62–1.18) | 0.35 | |
| Active HCC | 0.32 (0.21–0.49) | < 0.001 | 0.58 (0.36–0.94) | 0.03 | |
| CKD, eGFR < 60 | No | 1 (Referent) | 1 (Referent) | ||
| Yes | 0.67 (0.52–0.87) | 0.003 | 0.85 (0.63–1.13) | 0.26 | |
| HBV co-infection | No | 1 (Referent) | |||
| Yes | 1.54 (0.72–3.27) | 0.27 | – | – | |
| HIV co-infection | No | 1 (Referent) | |||
| Yes | 4.25 (0.59–30.6) | 0.15 | – | – | |
| HCV RNA, IU/mL | ≤800,000 | 1 (Referent) | 1 (Referent) | ||
| >800,000 | 1.17 (0.97–1.41) | 0.10 | 1.01 (0.83–1.24) | 0.91 | |
| Genotypes | GT1 | 1 (Referent) | 1 (Referent) | ||
| GT2 | 0.89 (0.72–1.11) | 0.30 | 0.68 (0.42–1.09) | 0.11 | |
| GT3 | 0.60 (0.47–0.80) | 0.001 | 0.48 (0.29–0.81) | 0.01 | |
| GT4 | 0.33 (0.12–0.92) | 0.03 | 0.30 (0.09–0.94) | 0.04 | |
| GT6 | 1.72 (0.85–3.48) | 0.14 | 0.96 (0.43–2.18) | 0.93 | |
| DAA regimens | DCV/ASV | 1 (Referent) | 1 (Referent) | ||
| PrOD±RBV | 2.41 (1.69–3.43) | < 0.001 | 2.96 (2.00–4.36) | < 0.001 | |
| EBR/GZR | 3.50 (2.04–6.00) | < 0.001 | 3.73 (1.95–7.11) | < 0.001 | |
| SOF/LDV±RBV | 3.20 (2.45–4.17) | < 0.001 | 3.54 (2.63–4.76) | < 0.001 | |
| SOF/RBV | 1.61 (1.24–2.09) | < 0.001 | 1.96 (1.15–3.35) | 0.01 | |
| SOF/DCV±RBV | 1.44 (0.85–2.45) | 0.17 | 2.55 (1.27–5.12) | 0.01 | |
| GLE/PIB | 2.79 (1.84–4.23) | < 0.001 | 3.29 (1.95–5.57) | < 0.001 | |
| SOF/VEL±RBV | 1.79 (1.30–2.45) | < 0.001 | 3.07 (1.79–5.27) | < 0.001 | |
| Others | 1.62 (0.70–3.73) | 0.26 | 3.46 (1.34–8.93) | 0.01 | |
§5,995 patients with data for all variables, and 13,971 of 15,849 (88.2%) patients were included in the multivariable model, which does not include HBV and HIV. HBV and HIV were not used in the multivariable models since they were not significant predictors in the univariable analysis. HCV, Hepatitis C virus; HBV, Hepatitis B virus; HIV, Human immunodeficiency virus; CKD, Chronic kidney disease; eGFR, Estimated glomerular filtration rate; HCC, Hepatocellular carcinoma; GT, Genotype; SVR, Sustained virological response; DAA, Direct-acting antiviral; SOF, Sofosbuvir; VEL, Velpatasvir; RBV, Ribavirin; DCV, Daclatasvir; ASV, Asunaprevir; LDV, Ledipasvir; PrOD, Paritaprevir/ritonavir, ombitasvir + dasabuvir; EBR, Elbasvir; GZR, Grazoprevir; GLE, Glecaprevir; PIB, Pibrentasvir; CI, Confidence interval.